Portola Pharmaceuticals recently announced that its Bevyxxa drug was approved by the U.S. Food and Drug Administration (FDA) for treating adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complication. Read More »

Hi-Tech Pharmaceuticals, a company operating in the sports nutrition industry, has acquired Top Secret Nutrition, a developer of scientifically advanced, safely sourced, high quality and effective nutritional supplements. Read More »

The U.S. Patent Office published Citius Pharmaceuticals' patent application for enhanced stability of antimicrobial solutions for locking central venous catheters. Read More »

Rigel Pharmaceuticals Inc. recently announced that its New Drug Application (NDA) for the use of Tavalisse in treating chronic or persistent immune thrombocytopenia (ITP) has been filed by the U.S. Food and Drug Administration (FDA). Read More »

Population health management logistics just became easier for collective clients of two health-care administrative providers with MatrixCare’s acquisition of electronic health record (EHR) firm SigmaCare in the metropolitan New York area. Read More »

PharmaMar will present clinical data from Phase I and II studies examining Zepsyre’s effect on pediatric cancers and hematological disorders to the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration. Read More »

Immune Pharmaceuticals is enrolling patients in a Phase I and II clinical trial that will determine the safety and efficacy levels of Ceplene as a treatment for Chronic Myelomonocytic Leukemia. Read More »

ANI Pharmaceuticals Inc. recently made its U.S. launch of Diphenoxylate HCl and Atropine Sulfate Tablet to treat diarrhea. Read More »

One in four Americans taking certain prescribed medicines say they would stop taking them immediately—without consulting their doctor—after seeing ads promoting lawsuits against the drugs’ manufacturers, according to a new national survey released by the U.S. Chamber Institute for Legal Reform (ILR). Read More »

Imaging3 Inc. has hired Intertek Inc. to oversee hazard analytics and U.S. Federal Drug Administration guidance protocols during the submission of the company’s Dominion VI imaging device with patented SmartScan 3D technology. Read More »

Seattle Genetics Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration using data from its recent Phase 3 Alcanza trial and two Phase 2 investigator-sponsored trials of Adcetris. Read More »

With its identity coined by the founding optometrist’s own child, RevolutionEYES’ “Little Eyes” recently opened in Carmel, Indiana, launching a pediatric eye care clinic caring for youngsters between 6 months and 13 years old. Read More »

Biohaven Pharmaceutical Holding Co. has been granted Fast Track Designation for its product candidate Trigriluzole by the FDA. Read More »

Churchill Pharmaceuticals has expanded its Commercial Leadership Team. Read More »

Addressing a recently reported nationwide antacid scarcity, QuVa Pharma Inc. — specializing in critical drug shortage products — has rallied with supplies of its own pharmaceutical quality sodium bicarbonate formulation at the ready for U.S. hospital distribution. Read More »

To combat certain types of influenza, Lannett Co. Inc. can now market its Amantadine Hydrochloride Capsules USP in 100 mg. dose form following Food and Drug Administration approval of its Abbreviated New Drug Application. Read More »

Philadelphia-based Lannett Company Inc. recently obtained approval from the U.S. Food and Drug Administration (FDA) for its generic formulation of niacin in extended-release form, with the product available in both 500-mg and 1000-mg tablet doses. Read More »

Amgen recently presented 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society, which took place in Boston. Read More »

OncoSec Medical Inc.'s pIL-12 drug, also known as tavokinogene telsaplasmid, has been given an Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »

Amgen and Allergan's data supporting their Biologics License Application for ABP 215, a biosimilar candidate to Avastin (bevacizumab), will be reviewed by the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration by July 13. Read More »